Investigation of the relationship between miR-33a, miR-122, erythrocyte membrane fatty acids profile, and serum lipids with components of metabolic syndrome in type 2 diabetic patients
- PMID: 35531134
- PMCID: PMC9075026
- DOI: 10.4103/1735-5362.343078
Investigation of the relationship between miR-33a, miR-122, erythrocyte membrane fatty acids profile, and serum lipids with components of metabolic syndrome in type 2 diabetic patients
Abstract
Background and purpose: MicroRNAs (miRNAs) are small non-coding RNA molecules acting as critical regulators of post-transcriptional gene expression. MiR-33a and miR-122 have a crucial role in cholesterol and lipid metabolism. Therefore, their dysregulation may contribute to metabolic abnormality and their inhibition may be a useful therapeutic strategy. The objective of the present study was to investigate the relationship between miR-33a, miR-122, erythrocyte membrane fatty acids profile, and serum lipids with components of metabolic syndrome in an Iranian population suffering from type 2 diabetes mellitus (T2DM).
Experimental approach: Expression of miR-33a and miR-122 was measured by real-time polymerase chain reaction and erythrocyte membrane fatty acid profiles were analyzed by gas chromatography-mass spectrometry.
Findings/results: T2DM patients with and without metabolic syndrome had significantly higher miR-33a and miR-122 levels compared to controls. MiRNAs were significantly correlated with saturated fatty acid (SFAs), total SFAs/total polyunsaturated fatty acids (PUFAs) ratio, fasting plasma glucose, triacylglycerols, insulin and homeostatic model assessment of insulin resistance. In addition, there was a significant negative correlation between miR-33a and miR-122 levels and PUFAs, total PUFAs/total SFAs ratio and omega 6 fatty acids.
Conclusion and implications: Considering the roles of miR-33a and miR-122 in cholesterol and lipids metabolism, it may be concluded that the measurement of their expression may be useful as a potential additional biomarker for cardiometabolic derangement in T2DM patients. In addition, these findings may suggest that the inhibition of these miRNAs by anti-miRNA therapies may be explored as a potential therapeutic strategy.
Keywords: Erythrocyte membrane fatty acid profile; Metabolic syndrome; Type 2 diabetes; miR-122; miR-33a.
Copyright: © 2022 Research in Pharmaceutical Sciences.
Conflict of interest statement
The authors declared no conflicts of interest in this study.
Similar articles
-
Correlation of circulating miRNA-33a and miRNA-122 with lipid metabolism among Egyptian patients with metabolic syndrome.J Genet Eng Biotechnol. 2021 Oct 5;19(1):147. doi: 10.1186/s43141-021-00246-8. J Genet Eng Biotechnol. 2021. PMID: 34611771 Free PMC article.
-
Chronic administration of proanthocyanidins or docosahexaenoic acid reverses the increase of miR-33a and miR-122 in dyslipidemic obese rats.PLoS One. 2013 Jul 26;8(7):e69817. doi: 10.1371/journal.pone.0069817. Print 2013. PLoS One. 2013. PMID: 23922812 Free PMC article.
-
miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling.Proc Natl Acad Sci U S A. 2011 May 31;108(22):9232-7. doi: 10.1073/pnas.1102281108. Epub 2011 May 16. Proc Natl Acad Sci U S A. 2011. PMID: 21576456 Free PMC article.
-
MicroRNAs in metabolism and metabolic disorders.Nat Rev Mol Cell Biol. 2012 Mar 22;13(4):239-50. doi: 10.1038/nrm3313. Nat Rev Mol Cell Biol. 2012. PMID: 22436747 Free PMC article. Review.
-
Key regulatory miRNAs in lipid homeostasis: Implications for cardiometabolic diseases and development of novel therapeutics.Drug Discov Today. 2022 Aug;27(8):2170-2180. doi: 10.1016/j.drudis.2022.05.003. Epub 2022 May 10. Drug Discov Today. 2022. PMID: 35550438 Review.
Cited by
-
MicroRNAs as Biomarkers for Coronary Artery Disease Related to Type 2 Diabetes Mellitus-From Pathogenesis to Potential Clinical Application.Int J Mol Sci. 2022 Dec 29;24(1):616. doi: 10.3390/ijms24010616. Int J Mol Sci. 2022. PMID: 36614057 Free PMC article. Review.
-
Aerobic training and vitamin D modulate hepatic miRNA expression to improve lipid metabolism and insulin resistance in type 2 diabetes.Sci Rep. 2025 May 14;15(1):16764. doi: 10.1038/s41598-025-01757-x. Sci Rep. 2025. PMID: 40369056 Free PMC article.
-
Regulatory Roles of MicroRNAs in the Pathogenesis of Metabolic Syndrome.Mol Biotechnol. 2024 Jul;66(7):1599-1620. doi: 10.1007/s12033-023-00805-z. Epub 2023 Jul 1. Mol Biotechnol. 2024. PMID: 37393414 Review.
-
Biochemical, histological, and immunohistochemical study on the therapeutic effects and mechanism of coenzyme Q10 in type 2 diabetes mellitus.Res Pharm Sci. 2025 Mar 31;20(2):292-303. doi: 10.4103/RPS.RPS_74_24. eCollection 2025 Apr. Res Pharm Sci. 2025. PMID: 40444167 Free PMC article.
-
Time for micro-RNAs in steatotic liver disease: a case-control study.Front Endocrinol (Lausanne). 2024 Mar 14;15:1349524. doi: 10.3389/fendo.2024.1349524. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38549763 Free PMC article.
References
-
- Abou-Seif MA, Youssef AA. Evaluation of some biochemical changes in diabetic patients. Clin Chim Acta. 2004;346(2):161–170. DOI: 10.1016/j.cccn.2004.03.030. - PubMed
-
- Taskinen MR. Diabetic dyslipidemia. Atheroscle Suppl. 2002;3(1):47–51. DOI: 10.1016/s1567-5688(01)00006-x. - PubMed
-
- Thrainsdottir IS, Aspelund T, Thorgeirsson G, Hardarson T, Malmberg K, Sigurdsson G, et al. The association between glucose abnormalities and heart failure in the population-based Reykjavik study. Diabetes Care. 2005;28(3):612–616. DOI: 10.2337/diacare.28.3.612. - PubMed
-
- Nielson C, Lange T. Blood glucose and heart failure in nondiabetic patients. Diabetes Care. 2005;28(3):607–611. DOI: 10.2337/diacare.28.3.607. - PubMed
-
- Panagiotakos DB, Georgousopoulou EN, Pitsavos C, Chrysohoou C, Metaxa V, Georgiopoulos GA, et al. Ten-year (2002-2012) cardiovascular disease incidence and all-cause mortality, in urban Greek population: the ATTICA Study. Int Cardiol. 2015;180:178–184. DOI: 10.1016/j.ijcard.2014.11.206. - PubMed
LinkOut - more resources
Full Text Sources